Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
0.4800
-0.0200 (-4.00%)
Jan 22, 2026, 1:04 PM EST - Market open
Impact BioMedical Revenue
Impact BioMedical had revenue of $18.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $25.00K.
Revenue (ttm)
$25.00K
Revenue Growth
n/a
P/S Ratio
239.81
Revenue / Employee
$12,500
Employees
2
Market Cap
50.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 50.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Plus Therapeutics | 5.26M |
| NeurAxis | 3.36M |
| Aligos Therapeutics | 2.65M |
| ABVC BioPharma | 797.92K |
| iBio, Inc. | 500.00K |
IBO News
- 5 months ago - Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue - GlobeNewsWire
- 7 months ago - Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger - GlobeNewsWire
- 10 months ago - Impact Biomedical Inc. Announcement Stock Activity/Pricing - GlobeNewsWire
- 1 year ago - Impact BioMedical Inc. to Present at The Microcap Conference - GlobeNewsWire
- 1 year ago - Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker™ Technology Targeting Inflammatory Disease - GlobeNewsWire
- 1 year ago - Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates - GlobeNewsWire
- 1 year ago - Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue - GlobeNewsWire
- 1 year ago - Impact BioMedical Inc. Announces the Closing of its Initial Public Offering - GlobeNewsWire